Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Jun. 2025,
PCI Biotech Holding ASA paidkr0.00 Mil more to buy back shares than it received from issuing new shares.
It receivedkr0.00 Mil from issuing more debt.
It paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedkr0.00 Mil from paying cash dividends to shareholders.
It receivedkr0.00 Mil on other financial activities.
In all, PCI Biotech Holding ASAspentkr0.00 Mil on financial activities for the
six
months ended in Jun. 2025.
PCI Biotech Holding ASA (OSL:PCIB) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
PCI Biotech Holding ASA's issuance of stock for the
six
months ended in Jun. 2025 was kr0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
PCI Biotech Holding ASA's repurchase of stock for the
six
months ended in Jun. 2025 was kr0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
PCI Biotech Holding ASA's net issuance of debt for the
six
months ended in Jun. 2025 was kr0.00 Mil.
PCI Biotech Holding ASA receivedkr0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
PCI Biotech Holding ASA's net issuance of preferred for the
six
months ended in Jun. 2025 was kr0.00 Mil.
PCI Biotech Holding ASA paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
PCI Biotech Holding ASA's cash flow for dividends for the
six
months ended in Jun. 2025 was kr0.00 Mil.
PCI Biotech Holding ASA receivedkr0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
PCI Biotech Holding ASA's other financing for the
six
months ended in Jun. 2025 was kr0.00 Mil.
PCI Biotech Holding ASA receivedkr0.00 Mil on other financial activities.
PCI Biotech Holding ASA Cash Flow from Financing Related Terms
PCI Biotech Holding ASA Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for PCI Biotech Holding ASA's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCI Biotech Holding ASA Cash Flow from Financing Chart
PCI Biotech Holding ASA Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
PCI Biotech Holding ASA's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-0.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of kr-0.47 Mil mean?
PCI Biotech Holding ASA (OSL:PCIB) has a Cash Flow from Financing of kr-0.47 Mil as of Jun. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Cash Flow from Financing too high?
PCI Biotech Holding ASA's current Cash Flow from Financing is kr-0.47 Mil. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's Cash Flow from Financing compare to VRTX and REGN?
PCI Biotech Holding ASA's Cash Flow from Financing of kr-0.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Cash Flow from Financing is kr-0.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current Cash Flow from Financing of kr-0.47 Mil. The current Cash Flow from Financing is kr-0.47 Mil. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Cash Flow from Financing is kr-0.47 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score
Get the complete analysis for OSL:PCIB
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:PCIB has been successfully added to your 
